LF
Therapeutic Areas
Century Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CNTY-101 | Relapsed/Refractory B-cell Malignancies (e.g., NHL, CLL) | Phase 1 |
| CNTY-102 | Relapsed/Refractory AML & other CD123+ hematologic cancers | Preclinical |
| CNTY-107 | Multiple Myeloma | Preclinical |
| iT Cell Programs | Solid Tumors | Discovery/Preclinical |
| Autoimmune Programs | Undisclosed Autoimmune Diseases | Discovery |
Leadership Team at Century Therapeutics
O(
Osvaldo (Oz) Flores, Ph.D.
President & Chief Operating Officer
GR
Greg Russotti, Ph.D.
Chief Technology Officer
J(
Joseph (Joe) Jimenez
Chair of the Board of Directors
BF
Bardia Farahbod, M.D.
Chief Medical Officer
AF
Adrienne Farid, Ph.D.
Chief Strategy & Corporate Development Officer